Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non-small cell lung cancer treated with erlotinib.
erlotinib
non-small cell lung cancer
p63
prediction
prognostic
thyroid transcription factor one
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
12
11
2019
accepted:
16
04
2020
entrez:
30
7
2020
pubmed:
30
7
2020
medline:
30
7
2020
Statut:
ppublish
Résumé
While erlotinib is primarily administered to patients with non-small cell lung cancer with sensitizing epidermal growth factor receptor (EGFR) mutations, it is also prescribed to patients with wild type (wt) EGFR in higher lines of treatment. However, there is no predictive marker for erlotinib efficacy in patients with EGFR wt. Certain immunohistochemical (IHC) parameters, including thyroid transcription factor 1 (TTF1) and p63, have been reported to indicate predictive power in patients with EGFR wt. The present study focused on retrospective data from the University Hospital in Pilsen using the TULUNG register. TTF1 and p63 expression data were extracted from the hospital information system and merged with registry data to calculate progression-free survival (PFS) and overall survival (OS) rates. A cohort of 345 patients with adenocarcinoma (ADC) or squamous cell carcinoma (SCC) exhibited similar erlotinib efficacies when TTF1 and p63 were ignored. However, significant differences were reported in PFS and OS rates of a subgroup of 126 patients where TTF1 and p63 parameters were known. In a univariate analysis, group A (ADC TTF1+/p63-) achieved PFS of 2.6 months, group B (SSC TTF1-/p63+) 1.9 months and group C (did not fit into groups A or B, i.e., ADC TTF1-/p63+ or SCC TTF1+/p63-) 1.4 months (P=0.006). Median OS was 14.2, 19.1 and 5.3 months for A, B and C, respectively (P=0.002). Furthermore, a multivariate analysis demonstrated IHC markers to be the only significant parameters for PFS and OS. Group C had a negative prognostic factor for PFS [hazard ratio (HR), 1.812; P=0.02] and OS (HR=2.367; P=0.01). In conclusion, patients with EGFR wt and lung carcinomas without TTF1 and p63 expression typical for ADC (TTF1+/p633-) or SCC (TTF1-/p63+) do not appear to be suitable candidates for erlotinib treatment.
Identifiants
pubmed: 32724380
doi: 10.3892/ol.2020.11663
pii: OL-0-0-11663
pmc: PMC7377161
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1376-1382Informations de copyright
Copyright: © Svaton et al.
Références
Mod Pathol. 1999 Mar;12(3):318-24
pubmed: 10102618
Front Endocrinol (Lausanne). 2015 Apr 28;6:51
pubmed: 25972840
ESMO Open. 2018 Nov 1;3(6):e000327
pubmed: 30555723
Mol Clin Oncol. 2016 Jul;5(1):14-18
pubmed: 27330756
J Thorac Oncol. 2011 Aug;6(8):1392-9
pubmed: 21716147
Recent Results Cancer Res. 2018;211:1-17
pubmed: 30069756
Histol Histopathol. 2019 Nov;34(11):1269-1278
pubmed: 31062864
Diagn Cytopathol. 2017 Jul;45(7):598-603
pubmed: 28429425
Histopathology. 2012 Mar;60(4):531-46
pubmed: 21916947
Oncotarget. 2016 Nov 29;7(48):78985-78993
pubmed: 27738317
Breast Cancer Res Treat. 2017 Jun;163(3):475-484
pubmed: 28349272
Tumour Biol. 2017 Feb;39(2):1010428317691186
pubmed: 28218046
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
PLoS One. 2019 Apr 11;14(4):e0215135
pubmed: 30973926
J Cancer. 2018 Oct 20;9(22):4279-4286
pubmed: 30519330
Eur J Cancer. 2010 Mar;46(4):765-81
pubmed: 20116997
J Pathol. 2002 Sep;198(1):100-9
pubmed: 12210069
Expert Opin Pharmacother. 2018 Dec;19(18):2055-2062
pubmed: 30392436
Asian Pac J Cancer Prev. 2015;16(7):2987-91
pubmed: 25854394
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Vitam Horm. 2018;106:517-544
pubmed: 29407447
Eur Respir J. 2001 Dec;18(6):1059-68
pubmed: 11829087
Ann Oncol. 2006 Nov;17(11):1673-6
pubmed: 16980598
Oncol Lett. 2017 Jul;14(1):306-312
pubmed: 28693169
J Am Soc Cytopathol. 2017 Jul - Aug;6(4):170-175
pubmed: 31043270
Oncology. 2010;78(3-4):249-58
pubmed: 20523085
PLoS One. 2015 Jul 24;10(7):e0133859
pubmed: 26208325
J Thorac Oncol. 2010 Oct;5(10):1616-22
pubmed: 20736854
J Zhejiang Univ Sci B. 2012 Nov;13(11):855-66
pubmed: 23125078
Biochem Biophys Res Commun. 2018 Nov 10;505(4):1027-1031
pubmed: 30314701
Mol Cell. 1998 Sep;2(3):305-16
pubmed: 9774969
Thorac Cancer. 2015 May;6(3):288-95
pubmed: 26273374
Appl Immunohistochem Mol Morphol. 2002 Jun;10(2):103-9
pubmed: 12051626
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168